Literature DB >> 6238097

In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack.

C L Gately, L M Muul, M A Greenwood, S Papazoglou, S J Dick, P L Kornblith, B H Smith, M K Gately.   

Abstract

We have examined the ability of cultured human glioma cells to elicit allogeneic cytolytic lymphocyte responses in vitro in order to delineate properties of glioma cells that may contribute to their ability to escape cellular immune attack. When glioma cells were cultured together with allogeneic peripheral blood mononuclear cells (PBMC) in mixed lymphocyte-tumor cultures (MLTC), it was observed that cells from eight of 12 glioma lines were surrounded by clear pericellular "halos," which appeared to impede contact between PBMC and the glioma cells. Enzymatic, histochemical, and immunochemical studies indicated that these halos represented glycosaminoglycan (GAG) coats that contained hyaluronic acid (HA) as a major constituent. Electron microscopic studies demonstrated the presence of many thin microvillous processes spanning the width of the halos. The presence of GAG coats around glioma cells in MLTC reduced the generation of cytolytic T lymphocytes specific for antigens on the glioma cells. Likewise, these cell coats decreased the lysis of glioma cells by cytolytic lymphocytes, once generated. The production of thick coats of GAG by glioma cells was induced by interaction of glioma cells with a nondialyzable factor produced by PBMC in culture. This factor did not cause glioma cells to release increased amounts of HA into the medium, but rather increased the production of HA that remained associated with the glioma cell surface. The formation of thick, protective GAG coats by glioma cells as a result of their interaction with the PBMC-derived factor constitutes a nonspecific suppressor mechanism that may contribute to the ability of this class of human solid tumors to evade cellular immune attack.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238097

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro.

Authors:  M A Oberc-Greenwood; L M Muul; M K Gately; P L Kornblith; B H Smith
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

2.  T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.

Authors:  C M Henningsson; S Selvaraj; G D MacLean; M R Suresh; A A Noujaim; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion.

Authors:  Katyayni Vinnakota; Feng Hu; Min-Chi Ku; Petya B Georgieva; Frank Szulzewsky; Andreas Pohlmann; Sonia Waiczies; Helmar Waiczies; Thoralf Niendorf; Seija Lehnardt; Uwe-Karsten Hanisch; Michael Synowitz; Darko Markovic; Susanne A Wolf; Rainer Glass; Helmut Kettenmann
Journal:  Neuro Oncol       Date:  2013-09-05       Impact factor: 12.300

4.  Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.

Authors:  C Liu; B F Kimler; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

Review 5.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

6.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

7.  Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma.

Authors:  T Spruss; G Bernhardt; H Schönenberger; W Schiess
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Glycosaminoglycan changes in human gliomas. A biochemical study.

Authors:  A Bertolotto; M L Magrassi; L Orsi; C Sitia; D Schiffer
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

9.  Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.

Authors:  D S Markovic; K Vinnakota; S Chirasani; M Synowitz; H Raguet; K Stock; M Sliwa; S Lehmann; R Kälin; N van Rooijen; K Holmbeck; F L Heppner; J Kiwit; V Matyash; S Lehnardt; B Kaminska; R Glass; H Kettenmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-15       Impact factor: 11.205

10.  Interferon effect on glycosaminoglycans in mouse glioma in vitro.

Authors:  M Wiranowska; A K Naidu
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.